Loading...
Dernières publications
-
Dylan Moutachi, Janek Hyzewicz, Pauline Roy, Mégane Lemaitre, Damien Bachasson, et al.. Treadmill running and mechanical overloading improved the strength of the plantaris muscle in the dystrophin‐desmin double knockout (DKO) mouse. The Journal of Physiology, In press, ⟨10.1113/JP286425⟩. ⟨hal-04643936⟩
-
Medhi Hassani, Dylan Moutachi, Mégane Lemaitre, Alexis Boulinguiez, Denis Furling, et al.. Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy. PLoS ONE, 2024, 19, ⟨10.1371/journal.pone.0295700⟩. ⟨hal-04501283⟩
-
Antonio Atalaia, Dagmar Wandrei, Nawel Lalout, Rachel Thompson, Adrian Tassoni, et al.. EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. Orphanet Journal of Rare Diseases, 2024, 19 (1), pp.66. ⟨10.1186/s13023-024-03059-3⟩. ⟨hal-04460667⟩
-
Florent Porquet, Lin Weidong, Kévin Jehasse, Hélène Gazon, Maria Kondili, et al.. Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells. Molecular Therapy - Nucleic Acids, 2023, 32, pp.857 - 871. ⟨10.1016/j.omtn.2023.05.007⟩. ⟨hal-04287597⟩
-
Caroline Le Guiner, T Larcher, A Lafoux, G Toumaniantz, S Webb, et al.. Characterization of the muscular and cardiac diseases of the DMSXL mouse model, a transgenic mouse model for Myotonic Dystrophy type 1. American Society of Gene & Cell Therapy, May 2023, LOS ANGELES, United States. ⟨hal-04096181⟩
-
Dylan Moutachi, Mégane Lemaitre, Clément Delacroix, Onnik Agbulut, Denis Furling, et al.. Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. Clinical and Experimental Pharmacology and Physiology, In press, ⟨10.1111/1440-1681.13804⟩. ⟨hal-04146953⟩
Chiffres clés
135
Publications avec texte intégral
Open Access
53 %
Mots clés
Myotonic Dystrophy Type 1
Heart failure
Glucocorticoids
Acetylcholinesterase knockout mouse
Maximal force
Antisense oligonucleotides
CTG repeat instability
Brain
Gene therapy
CRISPRi
Therapy
Transgenic mouse model
Gene editing
Mouse models
Exercice
Desmin
Cell model
DMPK
Neuron
Hypoxia
PCR
Cytoskeleton
Expression
BIOLOGIE MOLECULAIRE
Muscular dystrophy
Glucocorticoid-receptor
Male
In vivo
Oligodendrocytes
Trinucleotide repeat expansion
Dystrophin
Dilated cardiomyopathy
Animals
Long read sequencing
Acute coronary syndrome
Antisense oligonucleotide
Quantitative microdialysis
Myotonic dystrophy
RNA splicing
DM1
Thérapie génique
Skeletal muscle
Autophagy
Diaphragm
Alternative splicing
Brain dysfunction
Central nervous system
Intermediate filament
Muscle
Transgenic mouse
Motoneuron
Dynamin 2
Myotonic Dystrophy type 1
Mouse model
GABA
RNA biology
Glutamate
GSK3
Endurance training
Acetylcholinesterase deficiency
Genotype phenotype correlation
Trinucleotide Repeat Expansion
Cardiac muscle
CTG repeats
Duchenne muscular dystrophy
CONGENITAL MYATHENIC SYNDROME
Aging
Astrocyte
Mice
Cell culture model
Knockout
Exercise
PacBio
AAV
Glial cells
Dystrophie Myotonique
ARN
Fibrosis
Dystrophie myotonique
Heart
Astrocytes
ACETYLCHOLINESTERASE
Cell penetrating peptide
CMS
KNOCKOUT MICE
Oligodendrocyte
RNA interference
Myotonic dystrophy type 1
Humans
Transcriptomics
CTG repeat contractions
Centronuclear myopathy
Myelin
CRISPR/Cas9
Myotonic Dystrophy
Gene Therapy
Myotonic dystrophy mouse models
DMSXL mice
MBNL
Myostatin